Procter & Gamble Health Ltd
NSE: PGHL BSE: 500126
₹5015
-47.50 (0.94%)
Wed, 28 Oct 2026, 10:45 pm
Market Cap (in Cr)8354.05
PE Ratio25.46
Dividend3.08
Health Technology
Pharmaceuticals: Major
24.5KProcter & Gamble Health Ltd Company History
1967
- Company incorporated on 26 April as private limited company.
1974
- 12,782 shares issued without payment in proportion 1:3.
1977
- 2,500 bonus shares issued in proportion 1:3.
1979
- 50,000 bonus shares issued in proportion 1:2.
1981
- Company converted to public limited company on 29 June.
- Non-resident equity holding reduced from 60% to 51%.
- Shares subdivided on 29 June.
- Issued 5,02,500 shares to Chemitra GmbH and 47,500 as rights to residents.
- Offered 7,02,067 shares for public subscription.
1985
- Privately placed 1,00,000 15% non-convertible debentures with Army Group Insurance Fund.
- Privately placed 2,00,000 15% non-convertible debentures with UTI.
1986
- Introduced drugs including Praziquantel, Septopal Beads, and anti-cancer drugs.
- 16,50,000 bonus equity shares issued in proportion 3:5.
1987
- Company acquired bulk drug unit at Indore manufacturing chloroquine phosphate.
- Company acquired significant shareholding in Suneeta Laboratories, Indore.
- 15,40,000 shares issued at premium of Rs 10 per share on rights and preferential basis.
1989
- Company launched diagnostics project.
- Company launched pharmaceutical formulation division for BDH trademark.
- Company offered 5,50,000 14% secured redeemable non-convertible debentures on rights basis.
1990
- Company name changed to BDH Pharmaceuticals Ltd.
- Company sold Indore plant to BDH Pharma for Rs 200 lakhs.
1991
- 29,70,000 bonus equity shares issued in proportion 1:2.
1992
- Company offered 5,55,428 zero interest fully convertible debentures on rights basis.
- Issued 27,772 zero interest debentures to employees.
- Issued 2,49,500 zero interest debentures to Emedia Export Company GmbH and 1,39,300 to Chemilia GmbH.
1993
- Company issued 30,91,224 equity shares to Merck AG to increase stake to 51%.
- Poor performance attributed to Indore plant sale and reduced Guaiazulene offtake to Japan.
1997
- Company redeemed 14% NCDs (Series II) aggregating Rs 55 million.
1998
- EMI operated five divisions: pharma, reagents, bulk drugs, diagnostics, pigments.
- E Merck India assigned Polybion brand to small scale manufacturer.
- Company redeemed one-third of 16.5% NCDs held by UTI.
1999
- E Merck decided against joint venture for OTC business.
- E Merck India positioned as largest vitamins market player.
- E Merck India planned introduction of premium laboratory chemicals.
2000
- E. Merck and Kopran entered co-marketing arrangement for atorvastatin.
2002
- Prof. Thomas Schereckenbach appointed as Additional Director.
- Mr. K. J. Mallya appointed as Company Secretary and Compliance Officer.
2004
- Merck signed Deed of Assignment with Biochem Pharmaceuticals.
2007
- Mr. K Shivkumar appointed as Additional Director.
2009
- Mr. Ralph Antonius Zaat appointed as Director replacing Dr. Hans Hermansson.
2010
- Company recommended final dividend of Rs. 20 per share.
- Merck KGaA and sanofi-aventis signed agreement for novel cancer combinations.
- Merck KGaA donation program supported Schistosomiasis control in Africa.
- FDA approved Egrifta for HIV-infected patients with lipodystrophy.
2011
- Merck KGaA intended to name Matthias Zachert to Executive Board.
- Merck appointed Frederic Wohlwend as CIO.
- Merck strengthened research cooperation with Israel.
- Merck received European approval for three pre-filled pen injectors for fertility treatment.
2012
- Merck donated 100 millionth tablet to treat Schistosomiasis.
- Standard & Poor’s raised Merck’s long-term credit rating to A-.
- Merck advanced to eighth place in Access to Medicine Index.
- Jon Baumhauer awarded Luther Rose.
- Merck Serono announced final efficiency program for Switzerland.
2013
- Merck invested in research partnerships in Israel.
2014
- Merck Serono formed global Oncology Partnership and Education Network (OPEN).
2015
- Merck Ltd moved corporate office to Godrej One, Mumbai.
- Merck acquired Ormet Circuits.
- Merck helped refugees in Lebanon.
- Merck and Pfizer advanced Phase III trials for Avelumab.
- Merck and Pfizer received positive EMA opinion for Avelumab orphan drug designation in Merkel Cell Carcinoma.
2016
- Merck expanded distribution agreement with Roche.
- Merck won R&D 100 Award for top invention.
- Merck outlined future strategic roadmap targeting 2018.
- Merck presented its first Russian Literary Prize.
2018
- P&G acquired Consumer Health Business of Merck KGaA, Darmstadt, Germany.
2019
- P&G Health launched PANACHE platform for medical students.
2020
- P&G Health partnered with PHFI for Digital Health Project at Goa under SEHAT CSR Program.
2021
- P&G Health partnered with Tata Trusts to advance nutritional status of women and children in Andhra Pradesh.
- P&G Health commemorated Iron Deficiency Day with GUINNESS WORLD RECORDS achievement.
2022
- P&G Health launched Na Na Anemia Bus Yatra across 20 cities for Iron Deficiency Anemia awareness.
- P&G Health partnered with Lakshya and Recycle India Foundation for sustainable pharmacy waste management.
- P&G Health brought global nerve care experts together for Peripheral Neuropathy awareness.
- P&G Health partnered with Apnalaya to improve maternal and newborn health in Mumbai slums.
2023
- P&G Health partnered with Indian Academy of Pediatrics for Sankalp: Sampoorna Swasthya school healthcare initiative.
- P&G Health launched Mobile Healthcare Unit with HelpAge India in Guwahati.
- P&G Health collaborated with Indian Medical Association to launch VitaM.I.N.D.S conclave.
- Polybion celebrated World Health Day and launched Pragati Utsav for Vitamin B Deficiency awareness.
2024
- P&G Health and HelpAge India collaborated to improve healthcare access in Palghar.
- P&G Health's Nasivion entered Asia Book of Records.
- P&G Health achieved GUINNESS WORLD RECORDS title for largest online photo album of people wearing pin badges.
